© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
February 07, 2022
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
January 31, 2022
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.
Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.
January 24, 2022
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.
January 17, 2022
A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.
Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.
January 10, 2022
Experts consider shortcomings in the identification and management of myelodysplastic syndromes.
Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.